Blog
38 Articles
Claudin May Be the Next Big Target in Pancreatic Cancer Treatment
Dr. Wungki Park leads a trial that uses a monoclonal antibody to target a protein that is common in pancreatic cancer.
Two New Immunotherapy Trials Aim to Make Therapy More Effective
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
Testing a Combination for Metastatic Pancreatic Cancer
A clinical trial tests an investigational drug, immunotherapy, and radiation in combination against advanced pancreatic cancer.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
Disappointing Results of a Phase II Trial Using Angiogenesis Inhibitor
Dr. Tanios Bekaii-Saab reports on the disappointing results of a trial combining an angiogenesis inhibitor and mFOLFIRINOX.
Researching More Second-Line Options for Pancreatic Cancer
Dr. Allyson Ocean explains the concept behind a novel second-line treatment being tested for metastatic pancreatic cancer.
A New Vaccine for Advanced Pancreatic Cancer
An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.
Multi-Site Precision Promise Study Opens
Dr. Vincent Picozzi explains how Precision Promise clinical trial will use a personalized approach for pancreatic cancer patients.
An Expanded Access Trial for Cancer Patients with Specific Mutations
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
Attacking Cancer’s Key Mechanisms to Treat Metastatic Pancreatic Cancer
A clinical trial for patients with metastatic pancreatic cancer uses the new drug SM-88 in combination with other agents, to attack the tumor metabolism.
Testing a New Approach to Treating Advanced Pancreatic Cancer
Scientists are testing a new drug that is an antagonist of stress hormone receptors, in combination with nab-paclitaxel, for advanced pancreatic cancer.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Slowing the Spread of Advanced Pancreatic Cancer
Researchers are testing a kinase inhibitor that is used to treat lung diseases, including a type of lung cancer, against pancreatic cancer.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.